Iradimed Corporation (NASDAQ:IRMD) Short Interest Up 18.2% in December

Iradimed Corporation (NASDAQ:IRMD) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 124,100 shares, a growth of 18.2% from the December 15th total of 105,000 shares. Approximately 1.6% of the company’s stock are short sold. Based on an average daily volume of 39,400 shares, the days-to-cover ratio is currently 3.1 days.

Iradimed Price Performance

NASDAQ IRMD traded up $0.81 on Friday, hitting $59.17. The stock had a trading volume of 50,168 shares, compared to its average volume of 37,022. The business’s fifty day moving average price is $54.76 and its 200 day moving average price is $50.17. The stock has a market cap of $749.68 million, a price-to-earnings ratio of 40.53 and a beta of 0.81. Iradimed has a 52-week low of $40.18 and a 52-week high of $59.31.

Iradimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were paid a dividend of $0.15 per share. The ex-dividend date was Friday, November 15th. This represents a $0.60 annualized dividend and a yield of 1.01%. Iradimed’s dividend payout ratio (DPR) is 41.10%.

Insider Buying and Selling

In other news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares of the company’s stock, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 37.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Iradimed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Huntington National Bank increased its holdings in shares of Iradimed by 51.3% during the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after acquiring an additional 504 shares in the last quarter. Gladius Capital Management LP grew its position in Iradimed by 126.6% during the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock worth $87,000 after purchasing an additional 965 shares during the last quarter. Quantbot Technologies LP raised its holdings in shares of Iradimed by 83.0% in the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 1,052 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Iradimed during the third quarter worth $126,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Iradimed during the third quarter valued at $147,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.